A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results

被引：0
|
作者：
Lakhani, Nehal J.
Hamid, Omid
Brana, Irene
Lostes-Bardaji, M. Julia
Gajate, Pablo
Lopez-Criado, Maria Pilar
Swiecicki, Paul
de Miguel, Maria J.
Gil-Martin, Marta
Moreno, Victor
Muller, Aixa Elena Soyano
Ortiz, Ana Gonzalez
Sun, Dylan
Modi, Dimple
Zheng, Wenjun
Jankovic, Vladimir
Salvati, Mark
Fury, Matthew G.
Cristea, Mihaela C.
机构：
[1] START Midwest, Grand Rapids, MI USA
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Inst Oncol, Barcelona, Spain
[5] Inst Oncol VHIO, Barcelona, Spain
[6] Ramon & Cajal Univ Hosp, Madrid, Spain
[7] Univ Texas MD Anderson Canc Ctr, Madrid, Spain
[8] Univ Michigan, Ann Arbor, MI 48109 USA
[9] START Madrid CIOCC, Madrid, Spain
[10] Inst Catala Oncol IDIBELL, Barcelona, Spain
[11] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[13] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2650
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [32] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [33] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [34] Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors
    Ohnuma, T.
    Holland, J. F.
    Goel, S.
    Wilck, E.
    Lehrer, D.
    Ghalib, M. H.
    Chaudhary, I.
    Wilhelm, F.
    Swami, U.
    Mani, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies
    Geoerger, Birgit
    Morland, Bruce
    Jimenez, Irene
    Frappaz, Didier
    Pearson, Andrew D. J.
    Vassal, Gilles
    Maeda, Patricia
    Kincaide, Jasmine
    Mueller, Udo
    Schlief, Sarah
    Teufel, Michael
    Ploeger, Bart A.
    Cleton, Adriaan
    Agostinho, Andrea C.
    V. Marshall, Lynley
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 142 - 152
  • [36] Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies
    Kurzrock, Razelle
    Wheler, Jennifer
    Hong, David S.
    Guo, Zhong
    Mulcahy, Mary F.
    Benson, Al B., III
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [37] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Jordan Berlin
    Ramesh K. Ramanathan
    John H. Strickler
    Deepa S. Subramaniam
    John Marshall
    Yoon-Koo Kang
    Robert Hetman
    Matthew W. Dudley
    Jiewei Zeng
    Caroline Nickner
    Hao Xiong
    Philip Komarnitsky
    Stacie Peacock Shepherd
    Herbert Hurwitz
    Heinz-Josef Lenz
    British Journal of Cancer, 2018, 118 : 938 - 946
  • [38] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deepa S.
    Marshall, John
    Kang, Yoon-Koo
    Hetman, Robert
    Dudley, Matthew W.
    Zeng, Jiewei
    Nickner, Caroline
    Xiong, Hao
    Komarnitsky, Philip
    Shepherd, Stacie Peacock
    Hurwitz, Herbert
    Lenz, Heinz-Josef
    BRITISH JOURNAL OF CANCER, 2018, 118 (07) : 938 - 946
  • [39] A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours
    El-Helali, A.
    Plummer, R.
    Jayson, G.
    Coyle, V.
    Drew, Y.
    Mescallado, N.
    Harris, N.
    Clamp, A.
    McCann, J.
    Kennedy, R.
    Cranston, A.
    Wilson, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
    S J Isakoff
    D Wang
    M Campone
    A Calles
    E Leip
    K Turnbull
    N Bardy-Bouxin
    L Duvillié
    E Calvo
    British Journal of Cancer, 2014, 111 : 2058 - 2066
12345